17 assets in Human Papillomavirus-Related Squamous Cell Carcinoma

Therapeutic assets addressing Human Papillomavirus-Related Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Human Papillomavirus-Related Squamous Cell Carcinoma	Christian Hinrichs	P2	B (60)
Fludarabine Human Papillomavirus-Related Squamous Cell Carcinoma	Christian Hinrichs	P2	B (59)
e7 tcr-t cells Human Papillomavirus-Related Squamous Cell Carcinoma	Christian Hinrichs	P2	B (58)
9-valent human papillomavirus recombinant vaccine Human Papillomavirus-Related Squamous Cell Carcinoma	Shanghai Bovax Biotechnology Co., Ltd.	P3	B (57)
Retifanlimab Human Papillomavirus-Related Squamous Cell Carcinoma	Jennifer Dorth	P2	CCC (53)
scg142 Human Papillomavirus-Related Squamous Cell Carcinoma	SCG Cell Therapy Pte. Ltd.	P1/2	CCC (48)
Alpelisib Human Papillomavirus-Related Squamous Cell Carcinoma	Pamela Munster	P1	CC (43)
Carboplatin Human Papillomavirus-Related Squamous Cell Carcinoma	Pamela Munster	P1	CC (43)
Pyruvate Human Papillomavirus-Related Squamous Cell Carcinoma	Pamela Munster	P1	CC (43)
scg142 tcr-t cells Human Papillomavirus-Related Squamous Cell Carcinoma	The Affiliated Hospital of Qingdao University	P1	CC (43)
Tsc-200-A0201 Human Papillomavirus-Related Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-201-B0702 Human Papillomavirus-Related Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-202-A0201 Human Papillomavirus-Related Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-203-A0201 Human Papillomavirus-Related Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-A0101 Human Papillomavirus-Related Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-A0201 Human Papillomavirus-Related Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-C0702 Human Papillomavirus-Related Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)